Europese Unie - Maltees - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - preparazzjonijiet antianemiċi - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Europese Unie - Maltees - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radjonuklidi imaging - radjofarmaċewtiċi terapewtiċi - lumark huwa prekursur radjofarmaċewtiku. mhuwiex maħsub għal użu dirett f'pazjenti. din il-mediċina għandha tintuża biss għar-radjutikkettar ta 'molekuli ta' carrier, li ġew żviluppati u awtorizzati speċifikament għal radjutikkettar ma 'dan ir-radjonuklide.

Europese Unie - Maltees - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - il-prodotti terapewtiċi l-oħra kollha - renvela huwa indikat għall-kontroll ta 'iperfosfatemija f'pazjenti adulti li qed jirċievu emodijalisi jew dijalisi peritoneali. renvela huwa wkoll indikat għall-kontroll ta'l-iperfosfatemija fil-pazjenti adulti b'mard kroniku tal-kliewi mhux fuq dijalisi mal-fosforu fis-serum ≥ 1. 78 mmol/l. renvela għandu jintuża fi ħdan kuntest ta ' metodu terapewtiku multiplu, li jistgħu jinkludu l-suppliment tal-kalċju, 1,25-dihydroxy vitamin d3 jew wieħed mill-analogi tiegħu biex jikkontrollaw l-iżvilupp tal-marda fl-għadam tal-kliewi.

Europese Unie - Maltees - EMA (European Medicines Agency)

gmp-orphan sa - trientene tetraidroklorur - deġenerazzjoni epatoġenika - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - cuprior huwa indikat għall-kura ta 'wilson tal-marda fl-adulti, l-adoloxxenti u t-tfal ta' ≥ 5 snin li ma jittollerawx d-penicillamine-terapija.

Europese Unie - Maltees - EMA (European Medicines Agency)

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - radjonuklidi imaging - radjofarmaċewtiċi dijanjostiċi - biex jintuża biss għar-radjutikkettar ta 'molekuli ta' carrier, li ġew speċifikament żviluppati u awtorizzati għar-radjutikkettar ma 'dan ir-radjonuklide. prekursur radjufarmaċewtiku - mhux intenzjonat għall-użu dirett fil-pazjenti.

Europese Unie - Maltees - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Europese Unie - Maltees - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanedjol monohydrate - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogi użati fid-dijabete - qtern, taħlita fissa tad-doża ta saxagliptin u dapagliflozin, huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta metformin u/jew mediċina tat-tip sulphonylurea (su) u waħda mill-monokomponenti tal-qtern ma jipprovdux kontroll gliċemiku adegwat,meta diġà qegħdin jiġu ttrattati bil-kombinazzjoni ħielsa ta dapagliflozin u saxagliptin. (ara sezzjonijiet 4. 2, 4. 4, 4. 5 u 5. 1 għall-dejta disponibbli dwar il-kombinazzjonijiet studjat.

Europese Unie - Maltees - EMA (European Medicines Agency)

astrazeneca ab - metformin hydrochloride, saxagliptin, dapagliflozin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - qtrilmet huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta l-metformina flimkien jew mingħajr sulfonilurea (su) u jew saxagliptin jew dapagliflozin ma jipprovdux kontroll gliċemiku adegwat. meta diġà qed jiġu kkurati b'metformin u saxagliptin u dapagliflozin.

Europese Unie - Maltees - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Europese Unie - Maltees - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - għall-pazjenti b'dijabete tat-tip 2 mellitus:efficib huwa indikat bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku għal pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta 'metformin waħdu jew għal dawk li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta' sitagliptin u metformin. efficib huwa indikat f'kombinazzjoni ma ' sulphonylurea (i. terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. efficib huwa indikat bħala terapija ta 'kumbinazzjoni tripla ma' ppar-agonist (i. thiazolidinedione) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta ' metformin u agonista ppar. efficib huwa indikat ukoll bħala add-on għall-insulina (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti meta stabbli fid-dożaġġ ta' l-insulina u metformin waħdu ma jipprovdux kontroll gliċemiku adegwat.